ABSTRACT
Moclobemide was compared with isocarboxazide and clomipramine in patients with depression. A total of 167 outpatients were allocated to daily treatment with 300 mg moclobemide, 30 mg isocarboxazide or 150 mg clomipramine for 6 weeks. Moclobemide was slightly inferior to clomipramine, whereas isocarboxazide had an intermediate position. There was no interaction between treatment and atypical or nonatypical depression. Anticholinergic symptoms and orthostatic hypotension were most pronounced in the clomipramine group.
Subject(s)
Antidepressive Agents/therapeutic use , Benzamides/therapeutic use , Clomipramine/therapeutic use , Depressive Disorder/drug therapy , Isocarboxazid/therapeutic use , Adult , Aged , Depressive Disorder/classification , Depressive Disorder/psychology , Double-Blind Method , Female , Humans , Male , Middle Aged , Moclobemide , Psychiatric Status Rating ScalesABSTRACT
The purpose of this study was to compare moclobemide and clomipramine in reactive depression according to the Newcastle II classification. Sixty patients were allocated to either 300 mg moclobemide, 150 mg clomipramine or placebo, all divided in 3 daily doses. Improvements occurred over time, but differences between treatments and compared with placebo were never statistically significant. Dizziness, tremor and anticholinergic symptoms were significantly more frequent with clomipramine than with moclobemide and placebo.
Subject(s)
Adjustment Disorders/drug therapy , Antidepressive Agents/therapeutic use , Benzamides/therapeutic use , Clomipramine/therapeutic use , Adjustment Disorders/psychology , Adult , Aged , Antidepressive Agents/adverse effects , Benzamides/adverse effects , Clinical Trials as Topic , Clomipramine/adverse effects , Double-Blind Method , Female , Humans , Male , Middle Aged , Moclobemide , Psychiatric Status Rating Scales , Random AllocationABSTRACT
The results of three separate studies aimed at evaluating the efficacy of long-term, low-dose treatment with pivmecillinam alone, and in combination with pivampicillin, in patients prone to recurrent bacteriuria, are presented. Overall, pivmecillinam and pivmecillinam/pivampicillin appeared to be equally effective, both clinically and bacteriologically, in a group of elderly subjects treated for 6 months. Pivmecillinam was also used successfully for up to 1 year in 10 out of 12 children in whom prophylactic therapy was indicated. The various regimens employed were without any significant toxic effects and were well tolerated.
